Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.14 USD | +0.78% | +2.39% | +0.98% |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 38.65 | 37.13 | 42.92 | 61.94 | 47.26 | 39.45 |
Enterprise Value (EV) 1 | 45.89 | 36.84 | 45.7 | 62.02 | 53.94 | 55.16 |
P/E ratio | -16.7 x | -27.1 x | -42 x | -776 x | -18.9 x | -6.79 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 3.52 x | 2.71 x | 2.8 x | 3.22 x | 2.55 x | 2.26 x |
EV / Revenue | 4.18 x | 2.68 x | 2.98 x | 3.22 x | 2.91 x | 3.16 x |
EV / EBITDA | -73.3 x | 28 x | 47.3 x | 22.8 x | 286 x | -22 x |
EV / FCF | -18.4 x | -210 x | -21.2 x | -37.9 x | -11.7 x | -12.2 x |
FCF Yield | -5.43% | -0.48% | -4.72% | -2.64% | -8.54% | -8.17% |
Price to Book | 1.8 x | 1.28 x | 1.52 x | 1.9 x | 1.56 x | 1.58 x |
Nbr of stocks (in thousands) | 5,485 | 7,210 | 7,213 | 7,742 | 7,747 | 7,751 |
Reference price 2 | 7.046 | 5.150 | 5.950 | 8.000 | 6.100 | 5.090 |
Announcement Date | 3/22/19 | 3/27/20 | 3/30/21 | 3/30/22 | 3/29/23 | 4/1/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 10.99 | 13.72 | 15.34 | 19.24 | 18.57 | 17.47 |
EBITDA 1 | -0.6259 | 1.314 | 0.9669 | 2.719 | 0.1886 | -2.504 |
EBIT 1 | -2.147 | -0.9539 | -1.38 | 0.2574 | -2.299 | -5.221 |
Operating Margin | -19.54% | -6.95% | -9% | 1.34% | -12.38% | -29.88% |
Earnings before Tax (EBT) 1 | -1.86 | -1.267 | -1.032 | -0.0691 | -2.486 | -5.77 |
Net income 1 | -2.322 | -1.296 | -1.022 | -0.0783 | -2.494 | -5.775 |
Net margin | -21.13% | -9.44% | -6.66% | -0.41% | -13.43% | -33.05% |
EPS 2 | -0.4232 | -0.1900 | -0.1417 | -0.0103 | -0.3220 | -0.7500 |
Free Cash Flow 1 | -2.492 | -0.1753 | -2.156 | -1.636 | -4.606 | -4.509 |
FCF margin | -22.68% | -1.28% | -14.05% | -8.5% | -24.8% | -25.81% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 3/22/19 | 3/27/20 | 3/30/21 | 3/30/22 | 3/29/23 | 4/1/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | 7.24 | - | 2.79 | 0.09 | 6.69 | 15.7 |
Net Cash position 1 | - | 0.29 | - | - | - | - |
Leverage (Debt/EBITDA) | -11.58 x | - | 2.882 x | 0.0327 x | 35.45 x | -6.275 x |
Free Cash Flow 1 | -2.49 | -0.18 | -2.16 | -1.64 | -4.61 | -4.51 |
ROE (net income / shareholders' equity) | -10.2% | -5.11% | -3.57% | -0.26% | -7.92% | -20.9% |
ROA (Net income/ Total Assets) | -4% | -1.67% | -2.18% | 0.38% | -3.22% | -7.36% |
Assets 1 | 58 | 77.61 | 46.82 | -20.64 | 77.52 | 78.46 |
Book Value Per Share 2 | 3.900 | 4.020 | 3.920 | 4.210 | 3.920 | 3.220 |
Cash Flow per Share 2 | 0.4500 | 0.8700 | 0.9600 | 1.320 | 0.7500 | 0.1300 |
Capex 1 | 2.03 | 1.39 | 4.07 | 2.61 | 3.98 | 1.89 |
Capex / Sales | 18.48% | 10.14% | 26.54% | 13.56% | 21.41% | 10.83% |
Announcement Date | 3/22/19 | 3/27/20 | 3/30/21 | 3/30/22 | 3/29/23 | 4/1/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+0.98% | 40.22M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ICCC Stock
- Financials ImmuCell Corporation